Location Directory

Clinical trials in Phoenix, Arizona

This page shows live ClinicalTrials.gov search results for Phoenix, Arizona, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

8144

Shown on this page

Current sort

Institutions in Phoenix

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Mayo Clinic

Live official records

Open in full search

Conditions: Thoracic Organ Transplantation
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 14 Years to 80 Years
Enrollment: 991 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2034
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more

Conditions: Diabetes Mellitus, Chronic Kidney Diseases, Heart Diseases, Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: University of New Mexico; Other
Eligibility: 21 Years to 80 Years
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 3
States / cities: Phoenix, Arizona • Albuquerque, New Mexico • Black Rock, New Mexico

Conditions: Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Interventions: Pozelimab, Cemdisiran, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 158
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 125 more

Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oral Cavity Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Intensity-Modulated Radiation Therapy, Peposertib; Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 27
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more

Conditions: Non-erosive Reflux Disease
Interventions: BLI5100, Placebo; Drug
Lead sponsor: Braintree Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 788 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 112
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 92 more

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma
Interventions: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Lumbar Puncture, Mercaptopurine, Methotrexate, Positron Emission Tomography, Rituximab, Vincristine Sulfate; Drug · Procedure · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 54 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Phoenix, Arizona • Duarte, California • Irvine, California + 5 more

Conditions: Obesity, Overweight, Weight Maintenance
Interventions: VRB-101, Placebo; Drug
Lead sponsor: Verdiva Bio Dev Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 20
States / cities: Cullman, Alabama • Phoenix, Arizona • Tempe, Arizona + 16 more

Conditions: Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Interventions: ELA026; Drug
Lead sponsor: Electra Therapeutics Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more

Conditions: Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm, Brain Aneurysm
Interventions: Flow diversion; Device
Lead sponsor: phenox Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 21 more

Conditions: Atopic Dermatitis, Eczema, Atopic
Interventions: PF-08049820, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 17
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Huntington Beach, California + 9 more

Conditions: Alopecia Areata
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 63 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 78
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more

Conditions: Malignant Glioma
Interventions: Biopsy Procedure, Magnetic Resonance Imaging, Radiation Therapy, Selinexor; Procedure · Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 111
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 93 more

Clinical trials in Phoenix, Arizona

Filter and sort this location

Institutions in Phoenix

Live official records

Genome Transplant Dynamics

American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)